Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.

16 analysts have issued 1-year target prices for Vertex Pharmaceuticals' stock. Their VRTX share price forecasts range from $280.00 to $365.00. On average, they anticipate the company's share price to reach $328.38 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.

Vertex Pharmaceuticals' stock was trading at $288.78 at the start of the year. Since then, VRTX shares have increased by 9.1% and is now trading at $315.07.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our VRTX earnings forecast.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its earnings results on Tuesday, February, 7th. The pharmaceutical company reported $3.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.11 by $0.65. The pharmaceutical company earned $2.30 billion during the quarter, compared to analysts' expectations of $2.30 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 27.78% and a net margin of 37.20%. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.18 EPS.
Read the conference call transcript.

ETFs with the largest weight of Vertex Pharmaceuticals (NASDAQ:VRTX) stock in their portfolio include VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), Direxion mRNA ETF (MSGR), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), Pacer US Cash Cows Growth ETF (BUL), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Formidable Fortress ETF (KONG).

Vertex Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $9.55 billion-$9.70 billion, compared to the consensus revenue estimate of $9.60 billion.

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRTX stock can currently be purchased for approximately $315.07.

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $81.00 billion and generates $8.93 billion in revenue each year. The pharmaceutical company earns $3.32 billion in net income (profit) each year or $12.83 on an earnings per share basis.

The company employs 4,800 workers across the globe.

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.